Efficacy and Biomarker Explanation of AK-112 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2023-03-25
Target enrollment:
Participant gender:
Summary
This study aimed to explore the efficacy and biomarker explanation of AK112 Plus Lenvatinib
on extensive stage small cell lung cancer who failed from first line Atezolizumab plus
platinum based chemotherapy.